<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03151772</url>
  </required_header>
  <id_info>
    <org_study_id>1144-16</org_study_id>
    <nct_id>NCT03151772</nct_id>
  </id_info>
  <brief_title>Bioavailability of Disulfiram and Metformin in Glioblastomas</brief_title>
  <acronym>INSIDE</acronym>
  <official_title>Drug Level and Investigation of Novel Substances Indicated Downstream Effect in Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuro-oncological trials may fail due to the drug never getting to the intended target (i.e.&#xD;
      within the tumor micro environment). Also, changes' occurring in tumor cells when removed&#xD;
      from patients and grown in-vitro is another limiting factor influencing the clinical success.&#xD;
&#xD;
      Important questions are therefore:&#xD;
&#xD;
        1. Does the drug get there?&#xD;
&#xD;
        2. Does the drug do what it is intended to do?&#xD;
&#xD;
      To improve chances of clinical success there is a need for rational and intelligent selection&#xD;
      of potential drugs in future trials. This is an initiative for analyzing tumor concentration&#xD;
      of preoperative administered repurposed drugs&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Problems with including patients&#xD;
  </why_stopped>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Actual">September 24, 2020</completion_date>
  <primary_completion_date type="Actual">September 24, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Bioavailability study with an adaptive design (evaluation after 5 patients up to a total maximum of 20 patients in each arm). Experimental therapy not to be combined and not any comparison between therapies</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailabilty disulfiram</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Concentration of disulifram-copper complex available in glioblastoma compared to blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioavailabilty of metformin</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Concentration of metformin available in glioblastoma compared to blood</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Disulfiram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Disulfiram 200 mg twice daily and copper 2,5 mg once daily. For bioavailability purpose only, treatment is withdrawn postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 850 mg x 3 daily. For bioavailability purpose only, treatment is withdrawn postoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Disulfiram</intervention_name>
    <description>200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively</description>
    <arm_group_label>Disulfiram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 850 mg x 3 taken preoperatively</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The subjects must fulfill all the following inclusion criteria to be eligible for&#xD;
        participation in the study, unless otherwise specified:&#xD;
&#xD;
          1. A suspected glioblastoma (based on MRI) or recurrent glioblastoma undergoing surgical&#xD;
             resection.&#xD;
&#xD;
          2. Elective surgical indication&#xD;
&#xD;
          3. Age 18 years or older.&#xD;
&#xD;
          4. Karnofsky performance status of 60 - 100 (see attachment 3).&#xD;
&#xD;
          5. Not receiving another experimental treatment for glioblastoma at the moment of&#xD;
             inclusion.&#xD;
&#xD;
          6. Able to take oral medications.&#xD;
&#xD;
          7. No known allergy to substance&#xD;
&#xD;
          8. Absolute neutrophil count ≥ 1,500/mcL and platelets ≥ 100,000/mcL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General&#xD;
&#xD;
          1. Other likely diagnosis than glioblastoma based on MRI.&#xD;
&#xD;
          2. Pregnant and/or breastfeeding.&#xD;
&#xD;
          3. Women of childbearing potential who do not have a negative pregnancy test (not older&#xD;
             than 14 days) before inclusion.&#xD;
&#xD;
          4. History of active liver disease, including chronic active hepatitis, viral hepatitis&#xD;
             (hepatitis B, C and CMV), cholestatic jaundice of any etiology or toxic hepatitis or&#xD;
             inadequate hepatic function, defined as baseline ASAT and ALAT &gt; 1.5 X upper&#xD;
             institutional limit and/or bilirubin &gt; 1.5 X upper institutional limit.&#xD;
&#xD;
          5. Suspected significant raised intracranial pressure or other indication for emergent&#xD;
             surgery&#xD;
&#xD;
          6. Unfit for participation for any other reason judged by the including physician.&#xD;
&#xD;
        Specific additional exclusions criteria for disulfiram&#xD;
&#xD;
          1. History of uncontrolled hypertension (i.e. systolic BP &gt; 180 mmHg) and a diagnosis of&#xD;
             congestive heart failure&#xD;
&#xD;
          2. History of psychiatric conditions (e.g. depression, psychosis, schizophrenia) or&#xD;
             dementia.&#xD;
&#xD;
          3. History of Wilson's disease or family member with Wilson's disease (unless excluded as&#xD;
             a carrier by genetic test).&#xD;
&#xD;
          4. History of hemochromatosis or family member with hemochromatosis (unless excluded as a&#xD;
             carrier by genetic test).&#xD;
&#xD;
          5. Nickel hypersensitivity (disulfiram mobilize nickel causing a brief increase in nickel&#xD;
             concentrations before excretion. The initial increase may lead to hepatitis and&#xD;
             predisposed patients).7&#xD;
&#xD;
          6. Need for metronidazole, warfarin and/or theophylline medication (the metabolism may be&#xD;
             influenced by disulfiram).&#xD;
&#xD;
          7. Patients who are taking medications metabolized by cytochrome P450 2E1, including&#xD;
             chlorzoxazone or halothane and its derivatives (phenytoin, phenobarbital,&#xD;
             chlordiazepoxide, imipramine, diazepam, isoniazid, metronidazole, warfarin,&#xD;
             amitriptyline within 14 days prior to the first dose of disulfiram. Of note, lorazepam&#xD;
             and oxazepam are not affected by the P450 system and are not contraindicated with&#xD;
             disulfiram).&#xD;
&#xD;
          8. Addiction to alcohol or drugs. Alcohol must be avoided.&#xD;
&#xD;
          9. Serum/plasma copper and serum ceruloplasmin outside institutional limits. a. However&#xD;
             increased levels are seen together with ongoing acute phase reaction as determined by&#xD;
             elevated C-reactive protein (ceruloplasmin is elevated as part of the same process) it&#xD;
             is possible to retest after normalization of C-reactive protein.&#xD;
&#xD;
        Specific additional exclusions criteria for metformin&#xD;
&#xD;
          1. Diabetic patients or other patients where treating physician and/or anesthesiologist&#xD;
             consider may have an increased risk for lactic acidosis per- and postoperatively&#xD;
&#xD;
          2. Known renal failure, renal risk factors (including single kidney, donor kidney,&#xD;
             polycystic kidneys) or estimated glomerular filtration rate below 80 ml/min.&#xD;
&#xD;
          3. Congestive heart failure&#xD;
&#xD;
          4. Scheduled diagnostic work-up where contrast medium containing iodine is indicated&#xD;
&#xD;
          5. Concomitant use of NSAIDs (risk of renal injury)&#xD;
&#xD;
          6. Risk of dehydration judged by the treating physician (e.g. when symptoms include&#xD;
             vomiting)&#xD;
&#xD;
          7. Alcohol must be avoidance during treatment (increased risk of lactic acidosis)&#xD;
&#xD;
          8. Treatment with diuretics as they may increase risk of lactic acidosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asgeir S Jakola, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Asgeir S. Jakola</investigator_full_name>
    <investigator_title>Associate professor, neurosurgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Disulfiram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

